We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

1787:HKEXShandong Gold Mining Co., Ltd. Analysis

Data as of 2026-03-11 - not real-time

HK$40.64

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Shandong Gold Mining (1787.HK) is trading at HK$40.64, well above its DCF‑derived fair value of roughly HK$4.86, implying a substantial premium. The stock carries a trailing P/E of 36.6 and a forward P/E of 18, while the price‑to‑book sits at 5.44, suggesting it is **overvalued** relative to fundamentals. Revenue has surged 27% YoY and operating margins are modest at 12.3%, but the balance sheet is heavily leveraged with a debt‑to‑equity of over 100%, raising concerns about financial flexibility.
Technical indicators are mixed: the price is marginally above the 20‑day SMA, the MACD has turned bearish, and the RSI hovers near 50, indicating a neutral stance. Volume is trending up, supporting liquidity, yet volatility is high at over 80% on a 30‑day basis. The dividend yield of 0.87% is modest, but a payout ratio of 41% and solid operating cash flow suggest the payout is **sustainable**. Overall, the stock presents a growth narrative tempered by valuation and leverage risks, warranting a cautious positioning.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram indicating potential downside pressure
  • Significant overvaluation relative to DCF fair value
  • Support level at HK$37.10 providing a near‑term floor

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth (27% YoY) and improving forward EPS
  • High debt‑to‑equity ratio limiting financial flexibility
  • Modest dividend yield with sustainable payout

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Gold's status as a long‑term inflation hedge supporting demand
  • Elevated leverage and valuation pose downside risk
  • Geopolitical and regulatory environment in China adds uncertainty

Key Metrics & Analysis

Financial Health

Revenue Growth27.20%
Profit Margin4.88%
P/E Ratio36.6
ROE11.02%
ROA4.68%
Debt/Equity104.42
P/B Ratio5.4
Op. Cash FlowHK$18.3B
Free Cash FlowHK$1.9B

Technical Analysis

TrendNeutral
RSI49.5
SupportHK$37.10
ResistanceHK$44.60
MA 20HK$40.47
MA 50HK$40.98
MA 200HK$33.50
MACDBearish
VolumeIncreasing
Fear & Greed Index78.16

Valuation

Fair ValueHK$4.86
Target PriceHK$43.17
Upside/Downside6.23%
GradeOvervalued
TypeGrowth
Dividend Yield0.87%

Risk Assessment

Beta-0.01
Volatility80.74%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.